Company intelligence / Profile preview

Scanagen

United States

Ownership: Private
Development stage: Other

Overview

Scanogen has developed the SMART-ID assay and S1 Instrument for rapid identification of pathogens directly from whole blood within two hours. This enables faster targeted antimicrobial therapy for patients with suspected sepsis compared to traditional culture-based methods that take days. The technology is designed to reduce mortality, shorten hospital stays, and combat antimicrobial resistance by enabling precise treatment decisions[1].

Therapeutic areas: Infectious Diseases
Modalities: DeviceMolecular diagnostic assayBiologic (for detection purposes)
Industry: Molecular Diagnostics

Partnerships

Not specified in public sources as of June 2025.

Beyond the preview

Go deeper on Scanagen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Scanagen.

Explore the full profile